Viking Launches Phase 3 SUNRISE Program For Oral Obesity Drug VK2735
Viking Therapeutics (VKTX) began Phase 3 trials for its obesity drug VK2735, testing oral formulations in two 68-week studies with 560 adults each. The trials aim to assess efficacy and safety, with primary endpoints measuring weight change. VK2735 previously showed promising results in a Phase 2 study. The company reported $502M in cash reserves as of June 30, 2026, with its stock trading between $25.77 and $43.15 over the past year.
How this was made
The 30-second read
Why it matters
Initiating two Phase 3, randomized, double-blind, placebo-controlled trials with 68-week treatment and weight-change primary endpoints is a meaningful step that can shift probability-weighted outcomes and investor expectations for future data readouts.
Market read
Traders may reprice VKTX on the Phase 3 advancement catalyst, focusing on trial scale, endpoint structure, and how it compares to prior Phase 2 top-line signals.
What to watch
The article does not provide dosing safety signals, interim read timing, or expected enrollment start/completion dates, which can materially affect near-term valuation and trading.
Background
Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP receptor agonist, from earlier Phase 2 oral results into a larger Phase 3 obesity and type 2 diabetes-adjacent program.
Ticker impact
Viking launches SUNRISE Phase 3 for oral VK2735 in obesity and in overweight/obese adults with type 2 diabetes, with 68-week dosing and weight-loss endpoints.
Likely modest upside bias as investors price in advancement from Phase 2 to Phase 3, tempered by dilution and trial-risk concerns.
The article discloses new, company-specific Phase 3 program design (two randomized trials, sample sizes, dosing duration, primary endpoint), which is a tangible catalyst for biotech risk/reward repricing.
Market effects
Adds incremental competitive signal in the oral GLP-1/GIP obesity space, potentially affecting sentiment toward other oral metabolic programs.
Primarily US biotech sentiment; limited direct regional spillover beyond clinical-stage obesity peers.
Obesity drug development remains globally relevant, but this is company-specific trial initiation with no stated cross-border regulatory action.
Counterpoint
Phase 3 start does not guarantee success; investors may discount the news if trial design or endpoints are viewed as challenging versus prior Phase 2 results.
Key entities
- companyViking Therapeutics
Clinical-stage biopharmaceutical company running the SUNRISE Phase 3 program for VK2735.
- drug_candidateVK2735
Investigational oral and subcutaneous dual GLP-1 and GIP receptor agonist for obesity and metabolic disease.
- clinical_programSUNRISE Phase 3
Two randomized, double-blind, placebo-controlled multicenter trials (SUNRISE-1 and SUNRISE-2) with once-daily oral dosing for 68 weeks.
